JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature

JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature

Cutaneous T-cell lymphomas (CTCLs) are a group of lymphoid neoplasms with high relapse rates and no curative treatment other than allogeneic stem cell transplantation (allo-SCT). CTCL is significantly influenced by disruption of JAK/STAT signaling. Therefore, Janus kinase (JAK) inhibitors may be pro...

Full description

Bibliographic Details
Main Authors: Seyed Mohammad Vahabi, Saeed Bahramian, Farzad Esmaeili, Bardia Danaei, Yasamin Kalantari, Patrick Fazeli, Sara Sadeghi, Nima Hajizadeh, Chalid Assaf, Ifa Etesami
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Cancers
Subjects:
cutaneous T-cell lymphomas
CTCL
Janus kinase
JAK inhibitor
mycosis fungoides
subcutaneous panniculitis-like T-cell lymphoma
Online Access:https://www.mdpi.com/2072-6694/16/5/861

Internet

https://www.mdpi.com/2072-6694/16/5/861

Similar Items